Objective: Clinical trials play an important role in the development of healthcare. However, the current status of clinical trials on anti-PD-1/PD-L1 for nas...
The expression level of PD-L1, MSI, and ECOG performance status could be the predictors of achieving clinical benefit from anti-PD-1/anti-PD-L1 therapy in advanced gastroesophageal cancer.
Download scientific diagram | Evidence mapping of anti-PD-1/PD-L1drugs, citations, type of cancer and number of clinical trials (X-axis: anti-PD-1/PD-L1 drugs; Y-axis: citations; bubble color: type...
This review summarises the novel roles of ferroptosis, pyroptosis, and necroptosis in anti-PD-1/PD-L1 immunotherapy. Targeting non-apoptotic regulated cell death in combination with anti-PD1/PD-L1...
dose-finding clinical trials of its Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® or Opdivo...
Objective: Clinical trials play an important role in the development of healthcare. However, the current status of clinical trials on anti-PD-1/PD-L1 for nasopharyngeal carcinoma remains unclear. T...
Anti-PD-1/PD-L1 therapy holds promise as adjunctive therapy for chronic infectious diseases such as tuberculosis and HIV, and must therefore be tested in randomized clinical trials.
Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance. We assessed the antitumor activity and safety of BMS-936558, an antibody that spe...
ABSTRACT ; Introduction ; Neoadjuvant therapy ; Preclinical studies of combination therapy ; Clinical studies of combination therapy ; Safety and tolerability
however, few discoveries, despite validation within and across cohorts, have been successfully prospectively applied to clinical trials. Anti-PD-1 therapies have been approved for patients...